NMD Pharma A/S - CVR: 36899069

2022, EUR

04.07.2023

Bruttoresultat

-9.480'

Primær drift

-12.980'

Årets resultat

-12.324'

Aktiver

27.139'

Kortfristede aktiver

26.961'

Egenkapital

25.133'

Afkastningsgrad

-48 %

Soliditetsgrad

93 %

Likviditetsgrad

+500%

Resultat

04.07.2023

Årsrapport	2022 04.07.2023	2021 15.06.2022	2020 17.06.2021	2019 27.04.2020	2018 28.05.2019	2017 01.06.2018	2016 24.05.2017	2015 25.05.2016
Nettoomsætning
Bruttoresultat	-9.480.436	-11.029.051	-7.870.124	-7.132.039	-4.661.848	-17.857.762	0	0
Resultat af primær drift	-12.980.225	-14.252.927	-10.613.126	-9.145.166	-6.169.955	-25.620.167	-8.527.892	-26.073
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	0	0	0	0	0	51.230	0	0
Finansieringsomkostninger	-80.324	-97.715	-51.461	-92.667	-109.434	-1.234.852	-46.827	-1.270
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	-13.060.549	-14.350.642	-10.664.587	-9.237.833	-6.279.389	-26.803.789	-8.574.719	-27.343
Resultat	-12.323.989	-13.614.082	-9.928.027	-8.501.273	-5.542.829	-21.883.435	-6.872.801	-27.343
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

04.07.2023

Årsrapport	2022 04.07.2023	2021 15.06.2022	2020 17.06.2021	2019 27.04.2020	2018 28.05.2019	2017 01.06.2018	2016 24.05.2017	2015 25.05.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.140.480	1.023.009	1.962.593	887.557	894.485	5.581.651	2.096.395	31.002
Likvider	25.820.863	3.815.827	9.448.988	9.177.320	5.847.901	15.757.308	12.355.775	656
Kortfristede aktiver	26.961.343	4.838.836	11.411.581	10.064.877	6.742.386	21.338.959	14.452.170	31.658
Immaterielle aktiver og goodwill	0	0	0	0	0	0	0	0
Finansielle anlægsaktiver	82.611	80.910	76.968	0	0	0	0	0
Materielle aktiver	94.610	0	0	0	0	0	0	0
Langfristede aktiver	177.221	80.910	76.968	0	0	0	0	0
Aktiver	27.138.564	4.919.746	11.488.549	10.064.877	6.742.386	21.338.959	14.452.170	31.658

Aktiver

04.07.2023

Passiver

04.07.2023

Årsrapport	2022 04.07.2023	2021 15.06.2022	2020 17.06.2021	2019 27.04.2020	2018 28.05.2019	2017 01.06.2018	2016 24.05.2017	2015 25.05.2016
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	25.132.967	2.595.580	9.243.117	6.696	6.696	-8.733.578	13.149.857	22.658
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	201.313	201.313	63.455	0	0	0	0
Leverandører af varer og tjenesteydelser	1.526.017	1.669.170	1.446.566	1.465.474	773.502	2.570.658	838.626	0
Kortfristede forpligtelser	2.005.597	2.122.853	2.044.119	1.790.290	995.281	30.072.537	1.302.313	9.000
Gældsforpligtelser	2.005.597	2.324.166	2.245.432	1.853.745	995.281	30.072.537	1.302.313	9.000
Forpligtelser	2.005.597	2.324.166	2.245.432	1.853.745	995.281	30.072.537	1.302.313	9.000
Passiver	27.138.564	4.919.746	11.488.549	10.064.877	6.742.386	21.338.959	14.452.170	31.658

Passiver

04.07.2023

Nøgletal

04.07.2023

Årsrapport	2022 04.07.2023	2021 15.06.2022	2020 17.06.2021	2019 27.04.2020	2018 28.05.2019	2017 01.06.2018	2016 24.05.2017	2015 25.05.2016
Afkastningsgrad	-47,8 %	-289,7 %	-92,4 %	-90,9 %	-91,5 %	-120,1 %	-59,0 %	-82,4 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-49,0 %	-524,5 %	-107,4 %	-126.960,5 %	-82.778,2 %	250,6 %	-52,3 %	-120,7 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-16.159,8 %	-14.586,2 %	-20.623,6 %	-9.868,8 %	-5.638,1 %	-2.074,8 %	-18.211,5 %	-2.053,0 %
Soliditestgrad	92,6 %	52,8 %	80,5 %	0,1 %	0,1 %	-40,9 %	91,0 %	71,6 %
Likviditetsgrad	1.344,3 %	227,9 %	558,3 %	562,2 %	677,4 %	71,0 %	1.109,7 %	351,8 %

Resultat

04.07.2023

Gæld

04.07.2023

Årsrapport

04.07.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 04.07.2023)

Information om virksomhedens regnskabsklasse:The annual report of NMD Pharma A/S for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

04.07.2023

Dato for ledelsens godkendelse af årsrapporten:2023-06-23

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of NMD Pharma A/S for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases and develops small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels with a promising therapeutic potential in a range of neuromuscular diseases. Major activities and achievements in NMD Pharma are listed in the following. In February 2022, NMD Pharma raised new financing of EUR 35 million to further expand its clinical programs into several neuromuscular diseases and expand its pipeline against novel targets. The financing was led by Jeito Capital and included investments from existing NMD Pharma investors, INKEF Capital, Novo Holdings, Roche Venture Fund and Lundbeck Foundation. In September 2022, FDA granted Orphan Drug Designation for NMD670 for the treatment of myasthenia gravis. In October 2022, NMD Pharma reported positive top line results in a Phase I and proof of mechanism study of NMD670 in patients with myasthenia gravis confirming safety, tolerability and initial efficacy data in subjects suffering from neuromuscular disorders. In December 2022, NMD Pharma received clearance for its Investigational New Drug application from the US Food and Drug Administration to advance NMD670 into a Phase II clinical study in patients of spinal muscular atrophy Type 3.